rifaximin

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:administered_by oral tablet
gptkbp:approves gptkb:2004
gptkb:FDA
pregnant women
severe renal impairment
pediatric use
gptkbp:available_on generic medication
gptkbp:brand gptkb:Xifaxan
gptkbp:casnumber 80621-81-4
gptkbp:category gptkb:unknown
Category C
gptkbp:chemical_formula C43 H54 N4 O8 S
gptkbp:clinical_trial Phase III
gptkbp:clinical_use effective against E. coli
effective against C. difficile
effective against S. aureus
gptkbp:contraindication severe liver impairment
hypersensitivity to rifaximin
gptkbp:dosage_form gptkb:tablet
gptkbp:drug_interactions may interact with anticoagulants
may interact with other antibiotics
gptkbp:duration 14 days for hepatic encephalopathy
2 weeks for IBS-D
3 days for traveler's diarrhea
gptkbp:excretion primarily in feces
https://www.w3.org/2000/01/rdf-schema#label rifaximin
gptkbp:indication non-invasive bacterial infections
gptkbp:lifespan approximately 6 hours
gptkbp:manufacturer gptkb:Salix_Pharmaceuticals
gptkbp:mechanism_of_action inhibits bacterial RNA synthesis
gptkbp:metabolism minimal hepatic metabolism
gptkbp:pharmacokinetics poorly absorbed in the gastrointestinal tract
gptkbp:provides_guidance_on recommended for IBS-D treatment
recommended for hepatic encephalopathy management
not recommended for routine use in non-bacterial infections
gptkbp:research_focus antibiotic resistance
gut microbiome
chronic gastrointestinal disorders
gptkbp:route_of_administration oral
gptkbp:safety_features generally well tolerated
gptkbp:side_effect dizziness
headache
nausea
abdominal pain
flatulence
gptkbp:storage store at room temperature
gptkbp:strength 200 mg
gptkbp:used_for treatment of traveler's diarrhea
treatment of irritable bowel syndrome with diarrhea
treatment of hepatic encephalopathy
gptkbp:bfsParent gptkb:Rifadin
gptkbp:bfsLayer 5